Envoy Medical

COCH

Market cap $28.4M

Overview Fund Activity

1.32 USD

-0.02

1.49%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

1.39

+0.07

5.3%

1 day

-1.49%

5 days

3.94%

1 month

-2.22%

3 months

-5.71%

6 months

-13.73%

Year to date

-14.29%

1 year

-58.88%

5 years

-86.48%

10 years

-86.48%

About: Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.

Employees: 42

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

497% more capital invested

Capital invested by funds: $3M [Q1] → $17.9M (+$14.9M) [Q2]

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

48.25% more ownership

Funds ownership: 10.82% [Q1] → 59.06% (+48.25%) [Q2]

5% more funds holding

Funds holding: 22 [Q1] → 23 (+1) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

See Fund Rankings

Financial journalist opinion

Based on 6 articles about COCH published over the past 30 days

Envoy Medical Issues Letter to Shareholders and Provides Update on Recent Accomplishments

Highlights include Expanded Global Patent Portfolio, Complete Debt Elimination Strengthening Balance Sheet, and Further Momentum of Pivotal Clinical Trial White Bear Lake, Minnesota--(Newsfile Corp. - September 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today issued a letter to shareholders commenting on recent accomplishments and other operational updates from Chief Executive Officer, Brent Lucas. Dear Shareholders: The third quarter of 2025 has been one of tremendous progress and momentum for Envoy Medical.

Envoy Medical Issues Letter to Shareholders and Provides Update on Recent Accomplishments

Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology

Patents strengthen Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss. White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents.

Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology

Envoy Medical to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025

White Bear Lake, Minnesota--(Newsfile Corp. - September 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025 in New York City.

Envoy Medical to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025

Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant

No Serious Adverse Events or Unanticipated Device Effects Reported; Company Confirms Program Remains On Track White Bear Lake, Minnesota--(Newsfile Corp. - September 3, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today announced that the patients in the first stage of its pivotal clinical trial for the investigational Acclaim® fully implanted cochlear implant have successfully reached their three-month follow-up milestone. During this timeframe, no serious adverse events (SAEs) or unanticipated device effects (UADEs) were reported.

Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant

Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversion White Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A.

Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology

Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss. White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents across the United States, Australia, and Hong Kong.

Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology

Zacks Investment Research

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Tops Revenue Estimates

Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.27 per share a year ago.

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Tops Revenue Estimates

Envoy Medical Reports on Second Quarter 2025 Results

White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events. Financial and Corporate Highlights for Second Quarter and to date: Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.

Envoy Medical Reports on Second Quarter 2025 Results

Envoy Medical Expands Patent Portfolio with New Issuances in the United States

White Bear Lake, Minnesota--(Newsfile Corp. - July 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of two new patents, further strengthening its intellectual property portfolio in the United States. The U.S. Patent & Trademark Office has issued two additional patents to Envoy Medical: U.S. Patent No.

Envoy Medical Expands Patent Portfolio with New Issuances in the United States

Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia

White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia. The Australian Patent Office has issued the following three patents to Envoy Medical Corporation: Australian Patent No.

Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia

See News Rankings

Charts implemented using Lightweight Charts™